These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31554372)

  • 21. Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
    Kawamoto M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Kawabe K; Onishi H; Nakamura M; Morisaki T
    Anticancer Res; 2018 May; 38(5):2739-2748. PubMed ID: 29715094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
    Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
    Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
    Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
    Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
    [No Abstract]   [Full Text] [Related]  

  • 26. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
    Samatiwat P; Prawan A; Senggunprai L; Kukongviriyapan V
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jun; 388(6):601-12. PubMed ID: 25708948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
    Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation.
    Chen Y; Xu X; Wang Y; Zhang Y; Zhou T; Jiang W; Wang Z; Chang J; Liu S; Chen R; Shan J; Wang J; Wang Y; Li C; Li X
    J Exp Clin Cancer Res; 2023 Oct; 42(1):265. PubMed ID: 37821935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis.
    Armartmuntree N; Murata M; Techasen A; Yongvanit P; Loilome W; Namwat N; Pairojkul C; Sakonsinsiri C; Pinlaor S; Thanan R
    Redox Biol; 2018 Apr; 14():637-644. PubMed ID: 29169115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
    Ren HY; Chen B; Huang GL; Liu Y; Shen DY
    Mol Med Rep; 2016 Oct; 14(4):3602-8. PubMed ID: 27599527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
    Kamada M; Akiyoshi K; Akiyama N; Funamizu N; Watanabe M; Fujioka K; Ikeda K; Manome Y
    Oncol Rep; 2014 Aug; 32(2):829-34. PubMed ID: 24891233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular IL-33 Attenuates Extracellular IL-33-induced Cholangiocarcinoma Cell Proliferation and Invasion
    Yangngam S; Thongchot S; Vaeteewoottacharn K; Thuwajit P; Hermoso MA; Okada S; Thuwajit C
    Anticancer Res; 2021 Oct; 41(10):4917-4928. PubMed ID: 34593439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
    Huyen NT; Prachayasittikul V; Chan-On W
    J Hepatobiliary Pancreat Sci; 2016 Jul; 23(7):397-405. PubMed ID: 27107220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines.
    Yang J; Sontag D; Gong Y; Minuk GY
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1103-1109. PubMed ID: 33002234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
    Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
    Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
    Morton SD; Cadamuro M; Brivio S; Vismara M; Stecca T; Massani M; Bassi N; Furlanetto A; Joplin RE; Floreani A; Fabris L; Strazzabosco M
    Oncotarget; 2015 Sep; 6(28):26052-64. PubMed ID: 26296968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
    Qiu G; Ma D; Li F; Sun D; Zeng Z
    Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
    Intuyod K; Saavedra-García P; Zona S; Lai CF; Jiramongkol Y; Vaeteewoottacharn K; Pairojkul C; Yao S; Yong JS; Trakansuebkul S; Waraasawapati S; Luvira V; Wongkham S; Pinlaor S; Lam EW
    Cell Death Dis; 2018 Dec; 9(12):1185. PubMed ID: 30538221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
    Pei F; Tao Z; Lu Q; Fang T; Peng S
    World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.